LIR Life Sciences Corp. (CSE:SKNY)

LIR Life Sciences Balance Sheet

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jul 31, 2025	Apr 30, 2025	Apr 30, 2024
Cash & Equivalents	0	0.12	0.2
Cash & Short-Term Investments	0	0.12	0.2
Cash Growth	-	-38.01%	-
Other Receivables	0.01	-	0.01
Receivables	0.01	-	0.01
Total Current Assets	0.01	0.12	0.2
Total Assets	0.12	0.12	0.2
Accounts Payable	0.38	0.2	0.04
Short-Term Debt	0.04	-	0.19
Total Current Liabilities	0.41	0.2	0.23
Total Liabilities	0.41	0.2	0.23
Common Stock	0.3	0.3	0
Retained Earnings	-0.59	-0.45	-0.03
Comprehensive Income & Other	-	0.07	-
Shareholders' Equity	-0.29	-0.08	-0.03
Total Liabilities & Equity	0.12	0.12	0.2
Total Debt	0.04	-	0.19
Net Cash (Debt)	-0.03	0.12	0
Net Cash Growth	-	147336.58%	-
Net Cash Per Share	-0.00	0.02	0.01
Filing Date Shares Outstanding	18.95	18.95	0.01
Total Common Shares Outstanding	19	19	0.01
Working Capital	-0.4	-0.08	-0.03
Book Value Per Share	-0.02	-0.00	-2.11
Tangible Book Value	-0.4	-0.08	-0.03
Tangible Book Value Per Share	-0.02	-0.00	-2.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.